Skip to main content

Advertisement

Figure 1 | Journal of Medical Case Reports

Figure 1

From: Systemic sarcoidosis with bone marrow involvement responding to therapy with adalimumab: a case report

Figure 1

Concentrations of hemoglobin, white blood cells, and platelets over time. Concentrations of hemoglobin (mmol/L), white blood cells (×109/L), and platelets (×1011/L) at baseline and during the course of the patient's treatment. At diagnosis (Week 0), the patient began a prednisone regimen that was tapered after initiation of adalimumab treatment. Shaded areas indicate the first and second courses of adalimumab treatment. The patient discontinued adalimumab treatment between the 24th and 32nd weeks; adalimumab treatment was reinitiated at Week 33. Hbg, hemoglobin; PLT, platelets; WBC, white blood cells.

Back to article page